Dmp1 and tumor suppression

Oncogene

Volumn 26, Issue 30, 2007, Pages 4329-4335

  Inoue, K ^a   Mallakin, A ^a   Frazier, D P ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Arf; Cyclin D; Dmp1; Haplo insufficiency; p53; Ras

Indexed keywords

ARF PROTEIN; CYCLIN D; CYCLIN D BINDING MYB LIKE PROTEIN 1; ONCOPROTEIN; PROTEIN MYB; PROTEIN P16INK4A; PROTEIN P19; PROTEIN P19ARF; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CHROMOSOME 7Q; GENE EXPRESSION; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; MITOGENESIS; MYELOID LEUKEMIA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; SCREENING; SIGNAL TRANSDUCTION; SOLID TUMOR; TWO HYBRID SYSTEM; WILD TYPE;

ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; CYCLINS; E2F1 TRANSCRIPTION FACTOR; GENES, RAS; HUMANS; MICE; PROMOTER REGIONS (GENETICS); TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 34347342788     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210226     Document Type: Review

References (49)

1. Aslanian A, Iaquinta PJ, Verona R, Lees JA. (2004). Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev 18: 1413-1422.
2. Bernards R. (1999). CDK-independent activities of D type cyclins. Biochem Biophys Acta 1424(2-3): M17-M22.
3. Bieche I, Champeme MH, Matifas F, Hacene K, Callahan R, Lidereau R. (1992). Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet 339: 139-143.
4. Bodner SM, Naeve CW, Rakestraw KM, Jones BG, Valentine VA, Valentine MB et al. (1999). Cloning and chromosomal localization of the gene encoding human cyclin D-binding Myb-like protein (hDMP1). Gene 229: 223-228.
5. Brooksbank C. (2001). Tumor suppressors. One-hit wonders? Nature Rev Cancer 1: 174.
6. Calin GA, Croce CM. (2006). Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Semin Oncol 33: 167-173.
7. kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA 95: 1091-1096.
8. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949.
9. Crowe DL, Nguyen DC, Tsang KJ, Kyo S. (2001). E2F-1 represses transcription of the human telomerase transcriptase gene. Nucl Acid Res 29: 2789-2794.
10. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS et al. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
11. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. (1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658-2669.
12. Elmaagacli AH, Koldehoff M, Peceny R, Klein-Hitpass L, Ottinger H, Beelen DW et al. (2005). WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Leukemogenesis 90: 326-334.
13. Evers R, Grummt I. (1995). Molecular coevolution of mammalian ribosomal gene terminator sequences and the transcription termination factor TTF-1. Proc Natl Acad Sci USA 92: 5827-5831.
14. Ganter B, Fu S, Lipsick JS. (1998). D-type cyclins repress transcriptional activation by the v-Myb but not the c-Myb DNA-binding domain. EMBO J 17: 255-268.
15. Giacinti C, Giordano A. (2006). RB and cell cycle progression. Oncogene 25: 5220-5227.
16. Hirai H, Sherr CJ. (1996). Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1. Mol Cell Biol 16: 6457-6467.
17. Horstmann S, Ferrari S, Klempnauer KH. (2000). Regulation of B-Myb activity by cyclin D1. Oncogene 19: 298-306.
18. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y et al. (1997). Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89: 1405-1412.
19. Inoue K, Roussel MF, Sherr CJ. (1999). Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci USA 96: 3993-3998.
20. Inoue K, Sherr CJ. (1998). Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol Cell Biol 18: 1590-1600.
21. Inoue K, Sherr CJ, Shapiro LH. (1998a). Regulation of the CD13/aminopeptidase N gene by DMP1, a transcription factor antagonized by D-type cyclins. J Biol Chem 273: 29188-29194.
22. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al. (1994). WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84: 3071-3079.
23. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T et al. (1998b). Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 91: 2969-2976.
24. Inoue K, Wen R, Rehg JE, Adachi M, Cleveland JL, Roussel MF et al. (2000). Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev 14: 179 7-1809.
25. Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ. (2001). Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev 15: 2934-2939.
26. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. (1999). Tumor spectrum in ARF-deficient mice. Cancer Res 59: 2217-2222.
27. Kerr J, Leary JA, Hurst T, Shih YC, Antalis TM, Friedlander M et al. (1996). Allelic loss on chromosome 7q in ovarian adenocarcinomas:two critical regions and a rearrangement of the PLANH1 locus. Oncogene 13: 1815-1818.
28. Kim WY, Sharpless NE. (2006). The regulation of INK4/ARF in cancer and aging. Cell 127: 265-275.
29. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z et al. (2004). A combined computational-experimental approach predicts human microRNA targets. Genes Dev 18: 1165-1178.
30. Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. (2006). Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 9: 13-22.
31. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. (1998). Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 12: 3008-3019.
32. Lu Z, Luo RZ, Peng H, Huang M, Nishimoto A, Hunt KK et al. (2006). E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. Oncogene 25: 230-239.
33. Mallakin A, Taneja P, Matise LA, Willingham MC, Inoue K. (2006). Expression of Dmp1 in specific differentiated, nonproliferating cells and its repression by E2Fs. Oncogene 25: 7703-7713.
34. McMahon M, Woods D. (2001). Regulation of the p53 pathway by Ras, the plot thickens. Biochem Biophys Acta 1471: M63-M71.
35. Oh I-H, Reddy EP. (1999). The myb gene family in cell growth, differentiation, and apoptosis. Oncogene 18: 3017-3033.
36. ARF links the tumour suppressor p53 to ras. Nature 395: 125-126.
37. Palmero I, Murga M, Zubiaga A, Serrano M. (2002). Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2. Oncogene 21: 2939-2947.
38. Quon KC, Berns A. (2001). Haplo-insufficiency? Let me count the ways. Genes Dev 15: 2917-2921.
39. Rowland BD, Denissov SG, Douma S, Stunnenberg HG, Bernards R, Peeper DS. (2002). E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell 2: 55-65.
40. INK4a. Cell 88: 593-602.
41. Sherr CJ. (2000). The Pezcoller lecture:cancer cell cycle revisited. Cancer Res 60: 3689-3695.
42. Sherr CJ. (2001). The INK4a/ARF network in tumor suppression. Nat Rev Mol Cell Biol 2: 731-737.
43. Sherr CJ. (2006). Divorcing ARF and p53:an unsettled case. Nat Rev Cancer 6: 663-673.
44. Sherr CJ, Robers JM. (2004). Living with or without cyclin and cyclin-dependent kinases. Genes Dev 18: 2699-2711.
45. Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ, Inoue K. (2005). Ras-Raf-Arf signaling critically depends on Dmp1 transcription factor. Mol Cell Biol 25: 220-232.
46. Trovato M, Ulivieri A, Dominici R, Ruggeri RM, Vitarelli E, Benvenga S et al. (2004). Clinico-pathological significance of cell-type-specific loss of heterozygosity on chromosome 7q21: analysis of 318 microdissected thyroid lesions. Endocr Relat Cancer 11: 365-376.
47. Tschan MP, Fischer KM, Fung VS, Pirnia F, Borner MM, Fey MF et al. (2003). Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns. J Biol Chem 278: 42750-42760.
48. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M et al. (1996). Growth inhibition of human leukemic cells by WT1 antisense oligonucleotides. Blood 87: 2878-2884.
49. Zwijsen R, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides R. (1997). CDK-independent activation of estrogen receptor by cyclin D1. Cell 88: 405-415.